Dow Jones Industrial Average
) is trading up 88 points (+0.7%) at 12,622 as of Wednesday, Jun 27, 2012, 11:35 a.m. ET. During this time, 208.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 706.5 million. The NYSE advances/declines ratio sits at 2,335 issues advancing vs. 607 declining with 114 unchanged.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
The Dow component leading the way higher looks to be
), which is sporting a 72-cent gain (+1.1%) bringing the stock to $67.14. This single gain is lifting the Dow Jones Industrial Average by 5.45 points or roughly accounting for 6.2% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 7.6 million shares traded vs. an average daily trading volume of 15.2 million shares.
Johnson & Johnson has a market cap of $182.63 billion and is part of the
industry. Shares are up 1.3% year to date as of Tuesday's close. The stock's dividend yield sits at 3.7%.
Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. The company has a P/E ratio of 18.2, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Johnson & Johnson Ratings Report.